Product Description: Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases[1][2].
Applications: COVID-19-immunoregulation
References: [1]Povetacicept/[2]Evans LS, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023 Jul;75(7):1187-1202.
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Target: TNF Receptor